目錄:MedChemExpress LLC>>生化試劑>> Vedolizumab | MCE
CAS | 943609-66-3 | 純度 | 99.64% |
---|---|---|---|
分子量 | 146814.9 | 供貨周期 | 現貨 |
規格 | 5 mg | 貨號 | HY-P9911 |
應用領域 | 醫療衛生,化工,生物產業,制藥 |
MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務。
CAS No. : 943609-66-3
產品活性:Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
研究領域:Cytoskeleton
作用靶點:Integrin
In Vitro: Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06 μg/mL) and fibronectin (IC50=0.02 μg/mL), but not vascular cell adhesion molecule 1.
In Vivo: Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups.
相關產品:GRGDSPK | EILEVPST | Arg-Gly-Asp-Ser TFA | MK-0429 | Tirofiban hydrochloride monohydrate | Anti-Mouse IL-1a Antibody | Echistatin | TC113 | BIRT 377 | αvβ1 integrin-IN-1 | Enlimomab | Lys-Gln-Ala-Gly-Asp-Val | TC-I 15 | Valategrast hydrochloride | Carotegrast | Irigenin | Integrin modulator 1 | αvβ5 integrin-IN-1 | RGD | Abituzumab | Zaurategrast | Surfactin C1 | BOP sodium | Tirofiban-d9 | α2β1 Integrin Ligand Peptide TFA | Fradafiban | Firategrast | SB-273005 | Fibronectin
熱門產品線:重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫,我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物;
• 50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領;
• 產品種類涵蓋各種重組蛋白,多肽,常用試劑盒 ,更有 PROTAC、ADC 等特色產品,廣泛應用于新藥研發、生命科學等科研項目;
• 提供虛擬篩選,離子通道篩選,代謝組學分析檢測分析,藥物篩選等專業技術服務;
• 設有專業的實驗中心和嚴格的質控、驗證體系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告,確保產品的高純度、高品質;
• 產品的生物活性多經各國客戶實驗驗證;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業團隊跟蹤最新的制藥及生命科學研究進展,為您提供全球新的活性化合物;
• 與世界各大制藥公司及著名科研機構建立了長期的合作。